Tender detail
Open-house discount agreements for medicines containing depemokimab
Summary
The procurement concerns non-exclusive discount agreements for medicines containing the active ingredient depemokimab (ATC R03DX12). Agreements may be concluded at any time under the open-house model for the period from 1 January 2027 to 31 December 2028. Medicines included in the BfArM list of paediatric medicines under section 35(5a) of SGB V are excluded.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.